Recent Stories
Keeping the Human in Medicine: Two AI CoLab Researchers on What Machines Can’t ReplaceSomeone Is Hacking the Freezers. Pay Attention.Thinking of Running in 2028? Start HereWhat the Lame Duck Session Has to Do With the Ultimate 21st-Century Power Tool: RobotsBlack October Wasn't an Attack Wave. It Was a Warning.Extreme Ownership Means Ultimate Achievement – NASA Culture Shift
← Back to the board
Money

NIH awards Thomas Jefferson University contract HHSN272201700082C for advanced development of multivalent filovirus and Lassa fever vaccine candidates.

Why it’s here: A $26M NIH award for advanced development of multivalent filovirus and Lassa fever vaccines is biotechnology tied to biosecurity and pandemic preparedness, which the biotechnology scope covers.

Trace across the board

Item

Connected

12 links

About

  • National Institutes of Health
  • Department of Health and Human Services

Analytics cookies help us see how the site is used. They only run if you accept. Privacy Policy

NIH awards Thomas Jefferson University contract HHSN272201700082C for advanced development of multivalent filovirus and Lassa fever vaccine candidates. — The Wave